Effect of nebulizer type and antibiotic concentration on device performance

Pediatric Pulmonology

Volumn 23, Issue 4, 1997, Pages 249-260

  Weber, Allan ^a   Morlin, Greg ^a   Cohen, Morty ^b   Williams Warren, Judy ^b   Ramsey, Bonnie ^b   Smith, Arnold ^a  

^a University of Missouri   (United States)

^b NONE

Author keywords

aerosols; antibiotics; cystic fibrosis; jet nebulizer; particle size distribution; ultrasonic nebulizers

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; TOBRAMYCIN;

AEROSOL; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEBULIZER; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME; ULTRASOUND;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; CYSTIC FIBROSIS; EQUIPMENT DESIGN; HUMANS; HYDROGEN-ION CONCENTRATION; NEBULIZERS AND VAPORIZERS; OSMOLAR CONCENTRATION; PARTICLE SIZE; VISCOSITY;

EID: 0030898932     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199704)23:4<249::AID-PPUL2>3.0.CO;2-H     Document Type: Article

References (35)

1. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, Wentz K, Smith AL. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993: 328:1740-1746.
2. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, Gore EJ, Redding GJ. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol. 1989; 7:265-271.
3. Hudson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981; 2:1137-1139.
4. Steinkemp G, Tummler B, Gappa M, Albus A, Potel J, Doling G, Hardt H. Long term tobramycin aerosol in cystic fibrosis. Pediatr Pulmonol. 1989; 7:91-98.
5. Lifschiltz ML, Denning CR. Safety of kanamycin aerosols. Clin Pharmacol Ther. 1971; 12:91-95.
6. Dickie KJ, deGroot WJ. Ventilatory effects of aerosolized kanamycin and polymyxin. Chest. 1973; 63:694-697.
7. Alerson PO, Seeker-Walker RH, Strominger DB, Markham J, Hill RL. Pulmonary disposition of aerosols in children with cystic fibrosis. J Pediatr. 1974; 84:479-484.
8. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987; 136:1445-1449.
9. Gonda I. A semi-empirical model of aerosol deposition in the human respiratory tract after mouth inhalation. J Pharm Pharmacol. 1981; 33:692-696.
10. Lourenco RV, Cotromones E. Clinical aerosols I: Characterization of aerosols and their diagnostic tools. Arch Intern Med. 1982; 142:2163-2172.
11. Stahlhofen W, Gebhart J, Heyder J. Experimental determination of the regional deposition of inhaled aerosols in the human respiratory tract. Am Ind Hyg Assoc J. 1981; 41:385-398.
12. Lippman M, Albert RE. The effect of particle size on the regional deposition of inhaled aerosols in the human respiratory tract. Am Ind Hyg Assoc J. 1969: 30:257-275.
13. Weber A, Smith AL, Williams-Warren J, Ramsey B, Covert DS. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol. 1994; 17:331-339.
14. Mercer TT. Production and characterization of aerosols. Arch Intern Med. 1973; 131:39-50.
15. Mercer TT. Interpretation of cascade impactor data. Am Ind Hyg Assoc J. 1986; 26:236-241.
16. Clark AR. The use of laser diffraction for the evaluation of the aerosol cloud generated by medical nebulizers. Int J Pharm. 1995; 115:69-78.
17. Klein EF, Shah DA, Shah NJ, Modell JH, Desautel S. Performance characteristics of conventional and prototype humidifiers and nebulizers. Chest. 1973; 64:690-696.
18. Ferron AG, Derrebijn KE, Weber J. Properties of Aerosols Produced with Three Nebulizers. Amsterdam: Elsevier, 1985; 289-312.
19. Hess D, Horney BS, Snyder T. Medication - Delivery performance of eight small volume handheld nebulizers: Effects of diluent volume: gas flow rate, and nebulizer model. Respir Care. 1989; 34:717-723.
20. Hiller CF, Mazumder MF, Wilson JD, Renninger RG, Bone RC. Physical properties of therapeutic aerosols. Chest. 1981; 805: 901S-903S.
21. Asmundsson T, Johnson RF, Kilburn KH, Goodrich JK. Efficiency of nebulizers for depositing saline in human lung. Am Rev Respir Dis. 1973; 108:506-512.
22. Weber A, Chaffin D, Smith AL, Opheim KE. Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1985; 27:531-534.
23. Davis SS, Bubb MD. Physio-chemical studies on aerosol solutions for drug delivery. III. The effect of relative humidity on the particle size of inhalation aerosols. Int J Pharm. 1978; 1:303-314.
24. Kradjan WA, Lakshmincrayan S. Efficiency of air-compressor-driven nebulizers. Chest. 1985; 87:512-516.
25. Leeder JS, Spino M, Tesoro AM, MacLeod SM. High-pressure liquid chromatographic analysis of ceftazidime in serum and urine. Antimicrob Agents Chemother. 1983; 24:720-724.
26. Heertjes PM. Mass transfer to drops. Recent Adv Liquid-Liquid Extr. 1971:429-453.
27. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis. 1984; 129:211-215.
28. Schöni MH, Kraemer R. Osmolality changes in nebulizer solutions. Eur Respir J. 1989; 2:887-892.
29. Beasley R, Rafferty P, Holgate ST. Adverse reactions to the non-drug constituents of nebuliser solutions. Br J Clin Pharmacol. 1988; 25:283-287.
30. Fine JM, Gordon T, Thompson JE, Sheppard D. The role of titratable acidity in acid aerosol-induced bronchoconstriction. Am Rev Respir Dis. 1987; 135:826-830.
31. Lowry RH, Wood AM, Higenbottam TW. Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin Sci. 1988; 74:373-376.
32. Desager KN, Van Bever HP, Stevens WJ. Osmolality and pH of anti-asthmatic drug solutions. Agents Actions. 1990; 31:225-228.
33. Seidenberg J, Mir Y, von der Hardt H. Hypoxaemia after nebulised salbutamol in wheezy infants: The importance of aerosol acidity. Arch Dis Child. 1991; 66:672-675.
34. Goden AJ, Borland C, Lowry R, Higenbottam TW. Chemical specificity of coughing in man. Clin Sci. 1986; 70:301-306.
35. Elwood RK, Hogg JC, Pare PD. Airway response to osmolar challenge in asthma. Am Rev Respir Dis. 1982; 125(Suppl):61.